BioCryst Pharmaceuticals (BMV:BCRX *) - Aktienkurs, Nachrichten und Analyse

BCRX * Aktienübersicht

BioCryst Pharmaceuticals, Inc. ist ein Biotechnologieunternehmen, das orale niedermolekulare und Proteintherapeutika zur Behandlung seltener Krankheiten entwickelt.

Über das Unternehmen

BCRX * grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	4/6
Künftiges Wachstum	4/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	1/6
Dividenden	0/6

Belohnungen

75.1% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 66.18% pro Jahr

Risikoanalyse

Aktien sind hochgradig illiquide

Negatives Eigenkapital

Die Aktionäre wurden im vergangenen Jahr verwässert

BioCryst Pharmaceuticals, Inc. Wettbewerber

Genomma Lab Internacional. de

BMV:LAB B

Mex$21.2b

Nurix Therapeutics

NasdaqGM:NRIX

US$1.5b

Bicycle Therapeutics

NasdaqGS:BCYC

US$1.6b

Shanghai Henlius Biotech

SEHK:2696

HK$12.4b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für BioCryst Pharmaceuticals
Historische Aktienkurse
Aktueller Aktienkurs	US$170.00
52-Wochen-Hoch	US$170.00
52-Wochen-Tief	US$98.29
Beta	1.88
11 Monat Veränderung	0%
3 Monate Veränderung	n/a
1 Jahr Veränderung	n/a
33 Jahre Veränderung	-43.33%
5 Jahre Veränderung	n/a
Veränderung seit IPO	149.82%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	BCRX *	MX Biotechs	MX Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie BCRX * im Vergleich zur Branche MX Biotechs abschneidet.

Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie BCRX * im Vergleich zum MX Markt abgeschnitten hat.

Preisvolatilität

Is BCRX *'s price volatile compared to industry and market?
BCRX * volatility
BCRX * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiler Aktienkurs: BCRX * hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von BCRX * im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1986	536	Jon Stonehouse	www.biocryst.com

BioCryst Pharmaceuticals, Inc. ist ein Biotechnologieunternehmen, das orale niedermolekulare und Proteintherapeutika zur Behandlung seltener Krankheiten entwickelt. Das Unternehmen vermarktet Peramivir-Injektion, einen intravenösen Neuraminidase-Inhibitor zur Behandlung der akuten unkomplizierten Grippe unter den Namen RAPIVAB, RAPIACTA und PERAMIFLU, sowie ORLADEYO, einen oralen Serinprotease-Inhibitor zur Behandlung des hereditären Angioödems. Außerdem entwickelt es BCX10013, einen oralen Faktor-D-Inhibitor für komplementvermittelte Krankheiten.

BioCryst Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von BioCryst Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
BCRX * grundlegende Statistiken
Marktanteil	Mex$31.06b
Gewinn(TTM)	-Mex$2.88b
Umsatz(TTM)	Mex$7.53b

4.1x

Kurs-Umsatz-Verhältnis

-10.8x

Kurs-Gewinn-Verhältnis

Ist BCRX * zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
BCRX * Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$382.24m
Kosten der Einnahmen	US$202.37m
Bruttogewinn	US$179.86m
Sonstige Ausgaben	US$325.80m
Umsatz	-US$145.93m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.71
Bruttomarge	47.06%
Nettogewinnspanne	-38.18%
Schulden/Eigenkapital-Verhältnis	-176.1%

Wie hat sich BCRX * auf lange Sicht entwickelt?

Historische Performance und Vergleiche

BCRX * Aktienübersicht

Belohnungen

Risikoanalyse

BioCryst Pharmaceuticals, Inc. Wettbewerber

BMV:LAB B

Mex$21.2b

NasdaqGM:NRIX

US$1.5b

NasdaqGS:BCYC

US$1.6b

SEHK:2696

HK$12.4b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024

BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO

Recent updates

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024

BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$1.18 loss per share (vs US$1.33 loss in FY 2022)

Forecast to breakeven in 2026

BioCryst Launches Orladeyo (Berotralstat) in Italy

BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Forecast to breakeven in 2026

BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)

Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023

Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina

BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO

BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023

BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013

BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$0.32 loss in 2Q 2022)

BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Biocryst Pharmaceuticals, Inc. Announces Executive Changes

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

High number of new directors

BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health

High number of new directors

Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

High number of new directors

BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer

FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia

BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2021)

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

High number of new directors

BioCryst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250

Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swissmedic

Biocryst Announces Health Canada Has Authorized Orladeyo® (Berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

High number of new directors

First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.36 loss in 1Q 2021)

Erträge & Einnahmen